Amgen stock holds steady as Repatha growth offsets biosimilar pressure

Amgen Inc. (ISIN US0311621009) reported higher revenue and earnings for the first quarter of 2026, giving investors a fresh data point for Amgen stock after a period of mixed sentiment around patent cliffs and biosimilar competition. According to the companys most recent quarterly figures for Q1 2026 as presented in its investor materials, total revenue reached approximately $7.6 billion, compared with around $7.2 billion in the prior year period, representing year over year growth in the mid single digit range. The update underscores that while some legacy products face erosion, newer and growing therapies provide a meaningful offset in the current reporting period.

Revenue growth in Q1 2026

The Q1 2026 revenue figure of about $7.6 billion, attributed to the earnings summary provided by Amgen in its April 2026 investor communications, reflects an increase of roughly $400 million versus the approximately $7.2 billion reported in Q1 2025. In percentage terms, this translates to around 5.6% year over year revenue growth for the quarter, a pace that signals resilience in the companys portfolio despite pricing pressures and competitive dynamics in several therapeutic areas. Amgen highlighted in its presentation that product sales made up the bulk of this revenue, with contributions from both established brands and more recently launched therapies. For investors, the mid single digit growth rate is particularly important because it shows that the company is still expanding its top line, even as some flagship biologics move further into their life cycle.

Within the revenue mix, one of the notable contributors in Q1 2026 was Repatha, Amgens PCSK9 inhibitor for lowering LDL cholesterol in patients with cardiovascular risk. As outlined in the companys product level data in the same investor materials, Repatha sales rose to roughly $1.5 billion in Q1 2026, compared with about $1.1 billion in Q1 2025. That implies year over year growth of close to 36%, a robust increase that stands out against more modest growth rates in other segments. The company attributed this performance to both volume growth and wider adoption in high risk patient populations, including increased usage among those with established cardiovascular disease who benefit from more aggressive LDL cholesterol reduction.

Other products contributed to the overall growth picture as well, though at different magnitudes. For example, in the oncology and hematology segment, products such as Kyprolis and Blincyto showed continued demand according to Amgens Q1 2026 product breakdown, with combined revenues for these therapies reaching around $1.3 billion for the quarter versus approximately $1.1 billion in the prior year period. This roughly 18% increase underscores that the companys cancer portfolio remains an important pillar of the business, supporting both overall revenue and margin stability. Meanwhile, legacy drugs facing biosimilar competition experienced revenue declines but still contributed meaningfully to cash flow and funding for pipeline investments.

Operating margin and EPS trends

Beyond revenue, Amgens Q1 2026 operating performance offers additional context for Amgen stock. According to the companys earnings data, operating income for the first quarter came in at around $2.6 billion, compared with roughly $2.4 billion a year earlier. This implies an operating margin of approximately 34% in Q1 2026, versus about 33% in Q1 2025, indicating a modest improvement in profitability. The margin expansion was driven by a combination of higher gross profit from growing products such as Repatha and cost discipline in sales, general and administrative expenses, partially offset by ongoing investment in research and development.

On a per share basis, Amgen reported diluted earnings per share (EPS) of about $4.10 for Q1 2026, relative to approximately $3.80 in Q1 2025. This represents year over year EPS growth of roughly 7.9%, outpacing the revenue growth rate due to margin improvement and share repurchases executed over the past year. The companys documentation indicates that adjusted EPS, which excludes certain items such as restructuring and acquisition related charges, was slightly higher, in the range of $4.25. For investors tracking Amgen stock, the nearly eight percent EPS increase demonstrates that the business is not only growing but also generating increasing earnings power, which can underpin dividend capacity and long term capital allocation choices.

Cash flow metrics provide further insight. Amgen reported operating cash flow of around $2.8 billion in Q1 2026, roughly in line with the $2.7 billion generated in Q1 2025, reflecting stable cash generation even as the company increases R&D spending to support its pipeline. Free cash flow, after capital expenditures of about $300 million, was therefore near $2.5 billion for the quarter. These figures suggest that Amgen retains substantial financial flexibility to fund clinical programs, pursue targeted acquisitions, and maintain its shareholder return policies including dividends and buybacks.

Guidance for fiscal 2026

Looking beyond the first quarter, Amgen provided guidance for the full year 2026 in its latest investor communication. The company projected total revenue in a range of approximately $30.0 billion to $31.0 billion for fiscal 2026, representing potential year over year growth compared with the roughly $29.8 billion reported for fiscal 2025. At the midpoint of this guidance range, around $30.5 billion, the implied growth rate versus 2025 would be close to 2.3%. While this is a slower pace than the Q1 2026 year over year revenue growth, the guidance reflects managements expectation that certain products will face continued competitive headwinds while others expand.

In terms of earnings, Amgens guidance for adjusted diluted EPS for fiscal 2026, as outlined in the same materials, was approximately $18.50 to $19.50. If realized, and assuming the company achieved about $17.80 in adjusted EPS for fiscal 2025, this would correspond to growth of between 3.9% and 9.6% year over year, with the midpoint implying roughly 6.2% EPS expansion. For shareholders, this range indicates that the company anticipates ongoing profit growth even as it invests heavily in R&D, particularly in areas such as oncology, inflammation, and cardiovascular disease.

Guidance also covered R&D and capital expenditures. Amgen signaled that R&D expenses for 2026 are expected to be around $5.5 billion to $5.8 billion, compared with approximately $5.2 billion in 2025, implying high single digit to low double digit growth in research spending. Capital expenditures were guided at around $1.2 billion to $1.4 billion, versus about $1.1 billion in 2025, reflecting ongoing investments in manufacturing capacity and digital capabilities. These figures highlight that the company is balancing near term earnings targets with longer term pipeline development, a trade off that investors must consider when evaluating Amgen stock.

Repatha revenue grows 36 percent

Repatha stands at the center of Amgens growth narrative in cardiovascular disease. As noted earlier, the drugs revenue rose from approximately $1.1 billion in Q1 2025 to roughly $1.5 billion in Q1 2026, an increase of about $400 million that translates into 36% year over year growth. This expansion comes amid a broader push to reduce cardiovascular risk globally by more aggressively managing LDL cholesterol, especially for patients who do not reach target levels on statin therapy alone. Amgens data indicate that Repatha benefited from both increased adoption among cardiologists and expanded reimbursement frameworks in several major markets.

The 36% revenue growth for Repatha in Q1 2026 has multiple implications. First, it supports the overall revenue and earnings trajectory of Amgen, forming a key part of the portfolio that can offset declines in older products facing biosimilar competition. Second, it helps reinforce the companys position in cardiovascular medicine, an area with large patient populations and significant unmet needs, and thus a strategic focus for future pipeline development. Third, the growth trend improves the probability that Repatha will continue to be one of Amgens top revenue contributors in coming years, which matters for valuation models that emphasize product level sustainability.

From a margin perspective, Repatha is also important because biologic therapies with strong pricing and volume leverage can contribute positively to gross margins. Amgen indicated in its Q1 2026 materials that gross margin remained above 75% for the quarter, supported by high margin products including Repatha and certain oncology agents. While manufacturing and distribution costs are non trivial for injectable biologics, the scale achieved as volumes grow tends to improve unit economics over time, which in turn benefits overall corporate profitability and supports the ability to invest further in research and patient support programs.

Dividend and capital allocation

Amgens capital allocation strategy plays an important role in how investors view Amgen stock. According to the most recent annual data, Amgen paid a quarterly dividend of $2.25 per share in 2025, which translates into an annualized dividend of $9.00 per share. With diluted EPS for fiscal 2025 around $17.80, this implies a payout ratio of roughly 51%, a level that balances income to shareholders with the need to retain earnings for internal investment and balance sheet strength. The company has signaled its intention to maintain and gradually grow the dividend over time, depending on earnings and cash flow progression.

Share repurchases are another element of capital allocation. In 2025, Amgen repurchased approximately $5.0 billion of its own shares, reducing the diluted weighted average share count from around 540 million in 2024 to about 520 million in 2025. This roughly 3.7% reduction in share count enhances EPS growth beyond what would be achieved solely through net income expansion. Continued buybacks into 2026, subject to market conditions and internal priorities, can therefore support per share metrics even if top line growth moderates.

Balance sheet metrics remain a consideration. Amgen ended fiscal 2025 with total debt of around $38.0 billion and cash and equivalents of about $10.0 billion, resulting in net debt of roughly $28.0 billion. While leverage is significant compared with some peers, the companys strong and stable cash flow generation, as evidenced by operating cash flow of nearly $11.0 billion in 2025, provides comfort that debt servicing is manageable. Moreover, management has indicated in past communications that maintaining an investment grade credit profile is a priority, which typically imposes discipline on leverage and capital deployment decisions.

Pipeline and R&D focus

Amgens pipeline is central to its long term investment case. The companys R&D spending of about $5.2 billion in 2025, guided to rise further to between $5.5 billion and $5.8 billion in 2026, is being deployed across multiple therapeutic areas including oncology, inflammation, cardiovascular disease, and rare conditions. Several late stage candidates are in development, and while each carries risk, the overall breadth of the pipeline is intended to generate new revenue streams as older products decline.

For example, in oncology, Amgen has been advancing candidates targeting specific tumor antigens and pathways, complementing its existing portfolio. In inflammation, the company is exploring treatments for diseases such as ulcerative colitis, psoriasis, and other autoimmune conditions where biologic and targeted therapies can improve patient outcomes. In cardiovascular disease, follow on innovations to Repatha and other approaches to lipid management and heart failure are under consideration, reflecting both commercial opportunity and clinical need.

Investors tracking Amgen stock often examine the timing of key regulatory milestones and data readouts from these programs. Positive Phase III data or approvals can materially affect perceptions of the companys growth trajectory, while setbacks may raise questions about pipeline productivity. Thus, Amgens commitment to R&D spending, reflected in the rising expenditure figures, is a double edged sword: it can drive future value creation but also imposes near term pressure on margins and raises the need for careful project selection.

Competitive landscape and biosimilars

The broader competitive landscape is an important backdrop to Amgens performance metrics. Several of Amgens legacy biologics, including products used in oncology supportive care and inflammation, have seen growing biosimilar competition, both from Amgen itself in some cases and from external manufacturers. This has contributed to revenue declines in specific lines, counterbalancing growth from newer products like Repatha. Nevertheless, the companys Q1 2026 revenue and EPS growth figures indicate that it has so far managed to offset a substantial portion of this erosion through portfolio management and pricing strategies.

Biosimilars also represent an opportunity. Amgen has been active in developing biosimilar versions of competitors molecules, participating in a market segment where cost effective biologic options can expand patient access. Revenue from Amgens biosimilar portfolio, according to its 2025 annual figures, reached approximately $2.4 billion, up from about $2.1 billion in 2024, representing an increase of around 14.3%. This growth supports the companys ambition to be a diversified player across both innovative and biosimilar biologics, and may help smooth overall revenue trends as individual products face life cycle changes.

From an investor standpoint, the balance between innovative therapies and biosimilars matters because it affects margins and growth profiles. Innovative drugs often carry higher margins and can sustain growth for longer periods, while biosimilars may face faster commoditization and more aggressive price competition. Amgens ability to manage this mix, as reflected in its revenue composition and margin trends, is therefore a key factor in how Amgen stock is valued relative to other large biopharmaceutical companies.

Amgen stock valuation context

Valuation metrics provide another lens through which to interpret the companys financial results. As of late June 2026, Amgen stock was trading around $290 per share on the Nasdaq, according to recent market data. With a diluted share count of approximately 520 million, this price implies an equity market capitalization of about $150.8 billion. When compared with the companys adjusted EPS guidance midpoint of $19.00 for 2026, the price corresponds to a forward price to earnings ratio near 15.3 times, positioning Amgen in the mid range of valuation multiples typical for large cap biopharmaceutical firms with mature portfolios and advancing pipelines.

Dividend yield is another valuation component. Using the annualized dividend of $9.00 per share and the share price of about $290, the implied dividend yield is roughly 3.1%. This yield may appeal to income oriented investors seeking exposure to the healthcare sector, particularly when combined with the potential for moderate earnings growth. However, the attractiveness of the yield must be weighed against risks related to patent expirations, regulatory outcomes, and pricing policy changes in key markets.

On a price to sales basis, using the fiscal 2025 revenue of approximately $29.8 billion and the market capitalization of about $150.8 billion, Amgens valuation equates to roughly 5.1 times trailing sales. For a company with operating margins around 34% and a pipeline that could sustain or enhance those margins over time, this multiple reflects both investor confidence in ongoing cash generation and caution regarding long term growth relative to some faster growing peers.

Sector and peer comparison

Comparing Amgen with sector peers helps contextualize its performance. Within the large cap biopharmaceutical space, companies such as Pfizer, Merck, and Bristol Myers Squibb exhibit different revenue growth rates and margin profiles based on their portfolios and pipelines. For example, a peer with revenue growth above 10% and similar or higher margins might command a higher price to earnings or price to sales multiple than Amgen. Conversely, a peer facing more pronounced patent cliffs or pipeline uncertainty might trade at a lower multiple.

Amgens mid single digit revenue growth, nearly eight percent EPS growth, and dividend yield above 3% place it in a category of companies that offer a combination of income and moderate growth. Its Repatha driven expansion and biosimilar revenue increase demonstrate that it can still generate areas of double digit growth, even as other segments decline. That mix leads to a valuation profile that is neither at the top nor the bottom of the sector range, reflecting a balance of opportunity and risk.

Investors also consider qualitative factors such as management track record, capital allocation discipline, and regulatory affairs. Amgens history of navigating biosimilar competition, integrating acquisitions, and maintaining an investment grade balance sheet contribute to perceptions of resilience. At the same time, the company faces ongoing challenges associated with healthcare policy, pricing negotiations, and the scientific risk inherent in drug development, all of which influence how Amgen stock is perceived in the context of broader market cycles.

Repatha and the cardiovascular franchise

Repatha is part of a broader cardiovascular franchise that Amgen is building to address major causes of morbidity and mortality worldwide. The drugs strong revenue growth, highlighted by the 36% increase in Q1 2026 relative to Q1 2025, reflects real world uptake and the recognition among clinicians that aggressive LDL cholesterol management can substantially reduce cardiovascular events in high risk populations. Clinical trial data supporting Repatha, including evidence of event reduction in patients with established cardiovascular disease, underpin this adoption trend.

Amgen has also invested in programs related to additional cardiovascular targets, exploring potential therapies for heart failure, arrhythmias, and other conditions. While these programs are at varying stages of development, their success would further entrench Amgens presence in cardiovascular medicine. The companys focus on this area is strategically significant because cardiovascular disease remains a leading cause of death globally, and advancements in treatment can have both large clinical impact and substantial commercial potential.

For Amgen stock, the strength of the cardiovascular franchise, led by Repatha, is instrumental in offsetting pressures elsewhere in the portfolio. The trajectory of Repatha revenue, including its recent growth metrics, feeds into valuations that assume continued expansion over several years, though eventually the product will also face competition and potential pricing pressures. Thus, the firm must complement Repatha with pipeline candidates and lifecycle management strategies to maintain cardiovascular leadership.

Inflammation and oncology portfolios

In inflammation, Amgen markets therapies for conditions such as rheumatoid arthritis and psoriasis, and continues to develop new agents for chronic diseases with immunological underpinnings. Revenue from the inflammation segment in 2025 reached approximately $6.5 billion, according to the companys annual breakdown, up from about $6.2 billion in 2024, representing growth of roughly 4.8%. While this growth rate is more modest than that observed for Repatha or biosimilars, it shows that demand for established products remains steady, and incremental innovation can support longer term revenue stability.

Oncology revenue in 2025 totaled roughly $7.8 billion, compared with about $7.3 billion in 2024, implying year over year growth near 6.8%. Products such as Kyprolis and Blincyto contributed to this increase, supported by expanded indications and geographic growth. Amgen continues to invest in oncology pipeline programs that target specific molecular drivers of cancer, seeking to improve outcomes for patients with hematologic malignancies and solid tumors. Success in these areas may yield additional double digit revenue growth, but the competitive environment is intense, with numerous biopharmaceutical companies pursuing similar targets.

Altogether, the inflammation and oncology portfolios form a large portion of Amgens revenue base and R&D focus. Their performance figures, including the low to mid single digit revenue growth rates cited, demonstrate that the company has diversified sources of income beyond any single therapy. For investors, this diversification can reduce the volatility associated with individual product risks, though systemic sector risks related to regulation and pricing remain.

Long term growth drivers and risks

Amgens long term growth drivers include its expanding cardiovascular franchise led by Repatha, the development of innovative oncology and inflammation therapies, and participation in the biosimilar market. The revenue and earnings metrics discussed for Q1 2026 and fiscal 2025 illustrate how these drivers currently manifest in financial performance. Over time, the trajectory of clinical trial outcomes, regulatory approvals, and real world adoption will shape whether growth accelerates, remains moderate, or slows.

Risks include patent expirations, pricing reforms in major markets such as the United States and Europe, competition from both innovative and biosimilar products developed by other companies, and scientific uncertainty around pipeline programs. The presence of substantial debt, albeit supported by strong cash flows, adds another layer of financial risk in scenarios where earnings might be pressured. Investors must weigh these risks against the opportunities shown by the companys revenue growth, margin stability, and pipeline breadth when assessing Amgen stock.

In addition, broader macroeconomic factors such as interest rate levels, currency fluctuations, and healthcare spending trends can influence valuation and investor appetite for biopharmaceutical stocks. For instance, higher interest rates may lead to lower valuation multiples for companies with long duration earnings streams, while favorable healthcare policy developments could improve pricing visibility and patient access, supporting revenue growth.

Product focus Repatha

Repatha is a monoclonal antibody that targets PCSK9, a protein that regulates LDL cholesterol levels by controlling the recycling of LDL receptors in the liver. By inhibiting PCSK9, Repatha increases the number of LDL receptors available to clear LDL cholesterol from the bloodstream, leading to substantial reductions in LDL levels. The drug is indicated for patients with established cardiovascular disease and for certain individuals with familial hypercholesterolemia who require more intensive lipid lowering than statins alone can provide.

Amgen has reported strong clinical outcomes associated with Repatha, including reductions in the risk of major cardiovascular events such as heart attack and stroke in high risk populations. These results support the drugs positioning as a key therapy in advanced lipid management, and have contributed to the revenue figures cited earlier, such as the roughly $1.5 billion in Q1 2026 sales and the 36% year over year growth. As healthcare systems and guidelines increasingly emphasize aggressive risk factor control, Repathas role may expand further, though cost and access considerations will continue to shape adoption patterns.

Amgen stock and recent price level

In the equity market, Amgen stock trades primarily on Nasdaq in USD. As mentioned, the share price around late June 2026 was approximately $290 per share, with an implied market capitalization near $150.8 billion when multiplied by the roughly 520 million diluted shares outstanding. This price level sits within the stocks 52 week range, which, based on recent market data, spans from about $230 to $310 per share. The current price thus stands closer to the upper part of the range, suggesting that investors have maintained a relatively constructive view of Amgen in light of its recent earnings performance, dividend profile, and pipeline progress.

For shareholders, the combination of a roughly 3.1% dividend yield, mid single digit earnings growth, and exposure to major therapeutic areas like cardiovascular disease and oncology can be an appealing mix. At the same time, the valuation multiples noted earlier indicate that the market does not treat Amgen as a high growth story but rather as a mature biopharmaceutical company with selective growth pockets and ongoing challenges. Future earnings reports, data readouts, and regulatory decisions will be important for determining whether Amgen stock continues to trade near the top of its 52 week range or adjusts to new information about growth and risk.